<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699426</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2007-00405237</org_study_id>
    <nct_id>NCT00699426</nct_id>
  </id_info>
  <brief_title>The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes</brief_title>
  <acronym>Nexium</acronym>
  <official_title>The Effect of Nexium and Cardi-04 Yoghurt on Insulin Secretion and Effect and Cardi Vascular Risk Factors Associated With the Insulin Syndrome in Patients With Type 2 Diabetes - a Randomized Double-blind, Prospective, Placebo Controlled 2 x 2 Factorial Design 3 Month's Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lise Tarnow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effect of Nexium and probiotics on insulin secretion and cardiovascular risk&#xD;
      factors on type 2 diabetic patients.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
        1. Nexium causes an increased gastrin secretion that increases the insulin secretion and&#xD;
           thereby a reduction of HbA1c&#xD;
&#xD;
        2. Probiotics changes the gut flora and bloodpressure&#xD;
&#xD;
        3. Probiotics causes a change in inflammation and thrombosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Nexium + Yoghurt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexium + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+ Yoghurt</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nexium</intervention_name>
    <description>40 mg once daily is tested together with Yoghurt</description>
    <arm_group_label>Nexium + Yoghurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nexium</intervention_name>
    <description>nexium and placebo are tested</description>
    <arm_group_label>Nexium + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yoghurt</intervention_name>
    <description>Yoghurt</description>
    <arm_group_label>Placebo+ Yoghurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo+placebo</intervention_name>
    <description>placebo and placebo are tested.</description>
    <arm_group_label>placebo+placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes (WHO criteria) treated with metformin and/or sulfonylureas or diet&#xD;
&#xD;
          -  Males and females between 40 and 70 years&#xD;
&#xD;
          -  HbA1c between 6,0-10,0&#xD;
&#xD;
          -  Diabetes duration &gt; 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kidney disease (s-creatinine above the upper limit of normal range).&#xD;
&#xD;
          -  Liver disease (ALAT increase &gt; 3 times the upper limit of the normal range of ALAT).&#xD;
&#xD;
          -  Macroalbuminuria (urinary albumin excretion of &gt; 300 mg/day).&#xD;
&#xD;
          -  Heart failure(NYHA class lll or lV)&#xD;
&#xD;
          -  Severe neuropathy (symptoms + vibration perception threshold &gt; 50 measured by&#xD;
             biothesiometer.)&#xD;
&#xD;
          -  Neutropenia (neutrophil count&lt;2.0x10/l) or anemia (hemoglobin&lt;8mM for men or &lt;7mM for&#xD;
             women.&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Severe organic or metabolic diseases including cancer&#xD;
&#xD;
          -  C-peptide&lt; 0,3 pmol/l&#xD;
&#xD;
          -  Medicine interaction&#xD;
&#xD;
          -  Treatment with insulin&#xD;
&#xD;
          -  PPI or other medications for ulcus diseases&#xD;
&#xD;
          -  Treatment with warfarin or other coumarin derivations&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Allergy to medication used in the study&#xD;
&#xD;
          -  Participants may not participate in another clinical intervention trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan A. Vaag, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Lise Tarnow</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

